Company Performance Metrics
- Andreas Persidis: Co-Founder and CEO
- Sandra Thomas: Chief Accounting Officer
Biovista is a pioneer of AI and systematic drug repositioning.
They apply their systematic discovery Artificial Intelligence platform to develop their pipeline of repositioned drug candidates in disease areas such as neurodegenerative diseases, epilepsy, oncology and orphan diseases. They also work with their collaborators to proactively position
and to reposition their own assets, whether new chemical entities or existing compounds.
Their scientists use Biovista’s technology platform to analyze massive data resources and identify non-obvious, mechanism-of-action based associations between compounds, molecular targets and diseases.
They use this insight to find new uses for existing drugs or drug combinations, assess their risk profile and advance them to PoC and Clinical Phase IIa/b sooner, cheaper and with a higher probability of success than has been possible to date.
